BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37196067)

  • 21. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
    Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
    Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.
    Sapra P; Allen TM
    Clin Cancer Res; 2004 Apr; 10(7):2530-7. PubMed ID: 15073133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model.
    Mashreghi M; Zamani P; Karimi M; Mehrabian A; Arabsalmani M; Zarqi J; Moosavian SA; Jaafari MR
    Biotechnol Prog; 2021 May; 37(3):e3116. PubMed ID: 33369269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pros and cons of the liposome platform in cancer drug targeting.
    Gabizon AA; Shmeeda H; Zalipsky S
    J Liposome Res; 2006; 16(3):175-83. PubMed ID: 16952872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
    Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
    IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates.
    Mehrabadi FS; Adelmann J; Gupta S; Wedepohl S; Calderón M; Brinkmann U; Haag R
    Curr Cancer Drug Targets; 2016; 16(7):639-49. PubMed ID: 26853135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-Dependent Effect of Phenothiazines as Dynamin II Inhibitors on the Uptake of PEGylated Liposomes by Endocytic Cells and In Vivo Pharmacokinetics of PEGylated Liposomal Doxorubicin in Rats.
    Subasic CN; Butcher NJ; Simpson F; Minchin RF; Kaminskas LM
    Mol Pharm; 2023 Sep; 20(9):4468-4477. PubMed ID: 37548597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
    Gaillard PJ; Appeldoorn CC; Dorland R; van Kregten J; Manca F; Vugts DJ; Windhorst B; van Dongen GA; de Vries HE; Maussang D; van Tellingen O
    PLoS One; 2014; 9(1):e82331. PubMed ID: 24416140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
    Parker CL; McSweeney MD; Lucas AT; Jacobs TM; Wadsworth D; Zamboni WC; Lai SK
    Nanomedicine; 2019 Oct; 21():102076. PubMed ID: 31394261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
    Sun B; Deng C; Meng F; Zhang J; Zhong Z
    Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer.
    Deshpande P; Jhaveri A; Pattni B; Biswas S; Torchilin V
    Drug Deliv; 2018 Nov; 25(1):517-532. PubMed ID: 29433357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
    Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
    Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
    Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
    Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug.
    Lu WL; Qi XR; Zhang Q; Li RY; Wang GL; Zhang RJ; Wei SL
    J Pharmacol Sci; 2004 Jul; 95(3):381-9. PubMed ID: 15272215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.